BioSpace News Archive

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced the appointment of Michael Brooks to the newly created role of Chief Development Officer.

NanoDx, Inc., a privately held medical device company developing breakthrough, point-of-care diagnostic solutions, today announced a licensing agreement with IBM Research for use of its metal-oxide semi-conductive (“CMOS”) compatible nanoscale sensors to enhance and expand accurate, rapid testing for several indications, including COVID-19,

Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the appointment of Jean Chang to the position of Chief Operating Officer.

EV Biologics Corp, OTC PINK:YECO, today announced that it will distribute a dividend of one (1) Non-Fungible Token (NFT) for every 100 shares of YECO common stock held on the record date. Shareholders possessing less than 100 shares will not be eligible for this special dividend.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021.

Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the start of additional marketing initiatives focusing on the launch of a patient and physician experience program for GIMOTI, the Company’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis (DGP).

Cerus Corporation (Nasdaq: CERS), a company solely dedicated to safeguarding the global blood supply, and the Transfusion Service of the Swiss Red Cross (Blutspende SRK Schweiz) announced today the tenth anniversary of the use of the INTERCEPT Blood System for its entire platelet supply in Switzerland.

Pear Therapeutics Reports Nine-Month Real-World Healthcare Utilization Data for reSET-O ® . reSET-O ® , the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD).

Enable Biosciences is partnering with the California Department of Public Health (CDPH) in a statewide serosurvey program.

PharmaCyte Biotech, Inc. today announced that the production and shipping of test materials and study plan designs for the biocompatibility studies requested by the U.S. Food and Drug Administration (FDA) have been completed.